Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Johnson & Johnson will hand over $50 million to Emergent to settle their longstanding breach of contract dispute, according to an SEC filing. The companies had signed a multiyear Covid-19 vaccine manufacturing deal during the pandemic, but in 2022, Emergent said J&J should pay as much as $420 million because the pharma company ended their deal prematurely. Emergent has had to throw away millions of doses of J&J’s Covid vaccine, and was told by the FDA to stop producing it due to contamination issues.
Emergent also sold an empty building in Canton, MA, for $7 million, according to a Tuesday release detailing the company’s progress so far in improving its financial performance. Joe Papa joined the company as its new CEO earlier this year to drive the changes. Emergent also recently sold a site in Baltimore for $30 million.
Siegfried has named Marcel Imwinkelried as its new CEO starting in September, the CDMO said on Wednesday. Siegfried’s Former CEO, Wolfgang Wienand, started his new role as Lonza CEO this month.
Just – Evotec Biologics is building on its biosimilar development and commercial production partnership with Sandoz. The collaboration expansion could see more biosimilars be added to Sandoz’s portfolio, the companies said Monday. The two companies have been working together since May 2023.
The FDA told Korean biotech HLB and its license partner Jiangsu Hengrui Pharmaceuticals in a meeting that it can resubmit its NDA for rivoceranib in combination with camrelizumab in first-line unresectable hepatocellular carcinoma “without delay,” according to a Tuesday release. The agency rejected the drug combo in May due to GMP deficiencies and unfinished Bioresearch Monitoring clinical inspections due to travel restrictions.
Novo Nordisk Indonesia and Indonesia’s state-owned Bio Farma signed a memorandum of understanding to boost diabetes drug manufacturing in the country. “Novo Nordisk brings its expertise in diabetes care and insulin production to the collaboration, while Bio Farma brings its established local manufacturing capabilities,” the companies said Tuesday.
Charles River Laboratories will manufacture plasmid DNA for AAVantgarde’s Stargardt’s disease gene therapy, dubbed AAVB-039, the companies said on Monday.
MedPharm and Tergus Pharma have merged into one CDMO, with a focus on topical and transepithelial pharmaceuticals, according to a Monday release. The new entity will use MedPharm’s company name.
Boehringer Ingelheim said its new biomass power plant in Germany will help it save around 50,000 tons of carbon dioxide annually, a Monday release states.